Abstract
Overview
Introduction
A meager 20% of metastatic RCC tumors respond to standard cytokine therapy,
thus rendering 80% of advanced RCC patients without any effective treatment.
Further, with up to 50% of stage one to three patients relapsing following
nephrectomy and an increasing incidence of this disease, RCC represents a
lucrative commercial opportunity for the developers of novel, effective
pharmacotherapy.
Scope
- Overview of disease including epidemiology, biology of RCC, staging and
prognostic variables
- Review of current treatment controversies and physician opinion of
existing and future treatment strategies
- Examination of unmet needs in RCC treatment and market opportunities for
drug developers
- Profile of the four major novel molecular targeted therapies including
their therapeutic and commercial potential
Report Highlights
The high existing unmet need in the treatment of RCC is reflected by the poor
prognosis of patients with advanced stage disease, five- year survival rates
with existing cytokine therapy being less than 20% in this patient cohort.
The identification of biomarkers is set to revolutionize patient staging and
prognosis by individualizing patient treatments and creating novel drug
targets. Establishing the context in which innovative therapeutics are to be
integrated into existing practice will dramatically alter RCC treatment
paradigms.
Nexavar and Sutent, both indicated for metastatic RCC, look set to compete
well to the end of the decade. With Nexavar's first to market advantage and
Sutent's purported superior efficacy, revenue margins will lie extremely
close. Datamonitor forecasts Nexavar's 2010 revenues will reach $122 million
and Sutent's $179 million.
Reasons to Purchase
- Assess the impact on the market of the launch of four new RCC drugs, the
first new therapeutics for this indication in 10 years
- Identify opportunities for individualized patient treatment and novel drug
targets
- Plan strategic planning and product development, based on an understanding
of how novel therapeutics will alter current RCC treatment paradigms
| 
View Cart
